GlassScriptPhysician profile
Clara Coutee
NPI 1962406884
$2,447.08
in general payments reported to CMS, 2019-2025
25 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $288 · 2022: $486 · 2023: $526 · 2024: $713 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,673.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $517.95 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $369.52 | 2021-2025 | |
| Amgen INC. | $239.62 | 2023-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $235.07 | 2022-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $174.41 | 2021-2024 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $170.19 | 2021-2025 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $104.48 | 2022-2023 | Trintellix |
| Boston Scientific Corporation | $100.43 | 2021 | |
| Exact Sciences Corporation | $79.00 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $78.01 | 2023-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $70.50 | 2022-2023 | |
| Mylan Specialty L.P. | $47.44 | 2024 | Yupelri |
| Astellas Pharma US INC | $29.38 | 2023 | Myrbetriq, Veozah |
| Pfizer INC. | $26.71 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $24.40 | 2025 | Uzedy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $23.84 | 2023 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.77 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.85 | 2025 | Rexulti |
| Ardelyx, INC. | $20.73 | 2024 | Ibsrela |
| Medtronic, INC. | $18.58 | 2021 | |
| Sunovion Pharmaceuticals INC. | $16.50 | 2021 | |
| Merck Sharp & Dohme LLC | $15.41 | 2024 | Verquvo |
| Neurocrine Biosciences, INC. | $14.73 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.35 | 2023 | |
| Idorsia Pharmaceuticals US INC | $13.21 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clara Coutee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.